Immune checkpoint inhibitors (ICIs) mainly targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) activate antitumor immunity and provide a durable survival benefit [9], particularly in PD-L1-high NSCLC [10]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.